1h Free Analyst Time
Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. The analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.
Speak directly to the analyst to clarify any post sales queries you may have.
Market Overview
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 04: PIPELINE ANALYSISPART 08: CUSTOMER LANDSCAPE
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Executive Summary
Global Ovarian Cancer Drugs Market 2019-2023The analyst recognizes the following companies as the key players in the global ovarian cancer drugs market: AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche, Spectrum Pharmaceuticals, TESARO.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the research on novel diagnostics methods.”
According to the report, one of the major drivers for this market is the development of a strong pipeline for ovarian cancer is a requirement in the market, which is expected to propel the growth of the market.
Further, the report states that one of the major factors hindering the growth of this market is the lack of expertise and diagnostic methods is expected to hinder the growth of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca
- Clovis Oncology
- F. Hoffmann-La Roche
- Spectrum Pharmaceuticals
- TESARO